病期D2前立腺癌の予後因子 : 単変量及び多変量解析による検討

Abstract

235例を対象として, 予後因子を検討した. 1)単変量解析ではperformancestatus, ヘモグロビン値, 血清アルカリフォスファターゼ値, 血清LDH, 組織学的分化度, 骨転移の拡がり(EOD), 内分泌療法の反応性が重要な因子であった. 2)以上の7項目を全て施行した196例を対象として, Coxの比例ハザードモデルを用いて行った多変量解析では血清LDH, 内分泌療法の反応性, 組織学的分化度, 骨転移の拡がり(EOD)が重要な因子であった.以上より, 治療前LDHの高値のものと治療後のマーカーの正常化しないものは, 内分泌療法の高危険群であった

To evaluate prognostic factors in stage D2 prostate cancer, 235 patients who had been treated with endocrine therapy were investigated. With univariate analysis, performance status, hemoglobin concentration, serum alkaline phosphatase, LDH, histological grade, extent of disease (EOD), and response of tumor markers at 3 months were shown to be significant prognostic factors. To compare these 7 factors, multivariate analyses was performed in 196 cases. Cox proportional hazard model demonstrated that LDH, followed by response of tumor markers at 3 months, histological grade, and EOD were significant for predicting prognosis. We concluded that the patients whose serum LDH was above the normal range and/or whose tumor markers were not or had not been normalized 3 months after the onset of endocrine therapy were in the high risk group, and should be given more aggressive treatment.